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Abstract
We describe the synthesis of so far synthetically not accessible 3,6-substituted-4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazines as
nitrogen-rich heterocycles. The target compounds were obtained in five steps, including an amidation and a cyclative cleavage reac-
tion as key reaction steps. The introduction of two side chains allowed a variation of the pyrazolo[3,4-d][1,2,3]triazine core with
commercially available building blocks, enabling the extension of the protocol to gain other derivatives straightforwardly. Attempts
to synthesize 3,7-substituted-4,7-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazines, the regioisomers of the successfully gained 3,6-substi-
tuted 4,6-dihydro-3H-pyrazolo[3,4-d][1,2,3]triazines, were not successful under similar conditions due to the higher stability of the
triazene functionality in the regioisomeric precursors and thus, the failure of the removal of the protective group.
Introduction
The structural motif of pyrazolotriazines, particularly the pyra-
zolotriazinones, has drawn attention regarding a possible appli-
cation as therapeutic agents due to manifold biological activi-
ties. Amongst other known constitutional isomers such as
pyrazolo[4,3-e][1,2,4]triazines [1-3] and pyrazolo[1,5-
a][1,3,5]triazines [4-6], pyrazolo[3,4-d][1,2,3]triazines [7-34]
and their derivatives are literature known and subject of differ-
ent biological studies. Pyrazolo[3,4-d][1,2,3]triazines and their
derivatives, for example, were reported to function as anti-
cancer compounds [28,29,32], herbicides [19-21], antimicro-
bials [18], and pest control agents [35].
Several possibilities have been reported to gain the scaffold of
pyrazolo[3,4-d][1,2,3]triazines synthetically and successful syn-
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theses of different manifold isomers. 3,6-Dihydro-4H-
pyrazolo[3,4-d][1,2,3]triazin-4-ones 2, as one example of the
diverse compound class, can be gained via diazotization of
3-amino-1H-pyrazole-4-carboxamides 1a or 3-amino-1H-pyra-
zole-4-carbonitriles 1b and subsequent cyclization of the inter-
mediate diazo compounds under acidic conditions [22]
(Scheme 1).
Scheme 1: Synthesis of 3,6-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-
ones 2a,b by diazotization of 3-amino-1H-pyrazole-4-carboxamides 1a
or 3-amino-1H-pyrazole-4-carbonitriles 1b [22].
The structurally related 3,7-dihydro-4H-pyrazolo[3,4-
d][1,2,3]triazin-4-ones 3 (Figure 1) which are substituted in po-
sition N-7 can be obtained in the same manner as described in
Scheme 1, if the substitution position R1 in the starting
3-amino-1H-pyrazole-4-carboxamides 1a or 3-amino-1H-pyra-
zole-4-carbonitriles 1b is altered [26]. Furthermore, several 2,7-
dihydro-3H-imidazo[1,2-c]pyrazolo[4,3-e][1,2,3]triazines 4
were described. However, while 3,6-substituted-3,6-dihydro-
4H-pyrazolo[3,4-d][1,2,3]triazin-4-ones 2 and 3,7-substituted-
3,7-dihydro-4H-pyrazolo[3,4-d][1,2,3]triazin-4-ones 3 are re-
ported in several references dealing with their synthesis, modifi-
cation, and application [36], their non-oxidized derivatives 5
and 6 are yet, to the best of our knowledge, unknown in the lit-
erature.
Figure 1: Structural differences of several known (2–4) and so far
unknown (5 and 6) pyrazolo[3,4-d][1,2,3]-3H-triazine derivatives.
In the past, it was shown that ortho-methylamide-substituted
aryltriazenes 7 could be efficiently converted into 3,4-dihy-
drobenzo[d][1,2,3]triazine derivatives 8 [37] (Scheme 2).
Scheme 2: Synthesis of 3,4-dihydrobenzo[d][1,2,3]triazine derivatives
8 from triazene-containing precursors 7 [37].
In this context, triazenes have shown beneficial properties as
they can be used as protected diazonium species which can be
handled and converted in various transformations without
decomposition [37-39]. In the herein presented study, we
apply the cyclative cleavage reaction to pyrazolyltriazenes
instead of aryltriazenes, which results in the synthesis of diverse
pyrazolo[3,4-d][1,2,3]-3H-triazine derivatives 5.
Results and Discussion
According to the literature-known synthetic access to benzotri-
azines 8, we designed a retrosynthetic route consisting of five
steps to gain 4,6-dihydropyrazolo[3,4-d][1,2,3]-3H-triazines 5
and 4,7-dihydropyrazolo[3,4-d][1,2,3]-3H-triazines 6 starting
from pyrazolyltriazenes 15 (Scheme 3).
The sequence contains two key steps that have a major influ-
ence on the outcome of the reaction: (1) the addition of side
chains R1 to the core pyrazole ring system, which can occur in
position N-6 or N-7, and (2) the cyclative cleavage of the
triazene group of compounds 9 and 10 which should lead to the
target compounds 5 and 6. To carry out the designed synthetic
route, 3-(3,3-diisopropyltriaz-1-en-1-yl)-1H-pyrazole-4-carbo-
nitrile (15) was synthesized in a first step using the commercial-
ly available 3-amino-1H-pyrazole-4-carbonitrile (16). Thus, the
aminopyrazole was diazotized in aqueous media using hydro-
chloric acid and sodium nitrite. Diisopropylamine and an
aqueous solution of potassium carbonate were added to the
in-situ generated diazonium salt according to literature-known
protocols [40]. The resulting 3-(3,3-diisopropyltriaz-1-en-1-yl)-
1H-pyrazole-4-carbonitrile (15) was used as starting material
for the attempts to add different side chains to the pyrazole
moiety.
The addition of several aliphatic bromides or iodides 14 in com-
bination with potassium or cesium carbonate in DMSO gave a
mixture of the regioisomeric compounds 12 and 13 due to the
addition of the alkyl substituents to one of both pyrazole-
nitrogen atoms. As shown in Table 1, the alkylation protocol
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Scheme 3: Planned retrosynthesis to obtain 4,6-dihydropyrazolo[3,4-d][1,2,3]-3H-triazines 5 and 4,7-dihydropyrazolo[3,4-d][1,2,3]-3H-triazines 6 from
pyrazolylamines 16. DIPA = diisopropylamine.
Table 1: Synthesis of N-substituted pyrazoles 12 and 13.
entrya 14 (equiv) R1 X 12 (yield) 13 (yield)
1 14a (2.0) Bn Br 12a (54%) 13a (36%)
2 14b (1.5) tolyl-CH2 Br 12b (59%) 13b (40%)
3 14c (2.0) 3,5-difluorobenzyl Br 12c (48%) 13c (42%)
4b 14d (1.2) ethyl I 12d (34%) 13d (57%)
5b 14e (1.2) cyclopentyl Br 12e (39%) 13e (52%)
6 14f (1.2) isobutyl Br 12f (28%) 13f (47%)
7c 14g (1.1) EtO2COCH2 Br 12g (54%) 13g (15%)
8b 14h (2.0) 4-bromobenzyl Br 12h (51%) 13h (42%)
aTypical conditions for the conversion are: 15, Cs2CO3 or K2CO3 (1.2 equiv), 14 (1.1–2.0 equiv), DMSO, room temperature; the products 12 and 13
were separated by column chromatography. bThe conditions were varied in temperature (reaction temperature was 80 °C for entries 4 and 5 and
40 °C for entry 8. c0.95 equiv of K2CO3 were used.
did not give a selective conversion in favor of one of the gener-
ated isomers. The protocol was not changed or adapted to gain a
higher selectivity of one of the isomers, as both regioisomers
were used in the subsequent syntheses.
For the derivatives 12h and 13c, we were able to exemplarily
determine the molecular structure by X-ray crystallography,
proving the regioisomer obtained in the alkylation reaction
(Figure 2).
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Figure 2: Molecular structures of compounds 12h (A) and 13c (B) representing both possible regioisomers of the alkylation reaction (displacement
parameters are drawn at the 50% probability level). The X-ray data corroborate the obtained NMR data.
While isomer 12 was used for the synthesis of pyrazolo[3,4-
d][1,2,3]-3H-triazine derivatives of general structure 5, the
isomer 13 was intended to deliver pyrazolo[3,4-d][1,2,3]-3H-
triazine derivative of general structure 6. The synthetic se-
quence to compounds 5 is described in detail in the following
sections. The synthesis of the precursors to compound 6 derived
from 13 is shifted to Supporting Information File 1 as the cycla-
tive cleavage to the final product 6 failed in the last step of the
synthesis.
The conversion of 12 to the reduced aminomethyl compounds
17 was challenging. While the reduction with LiAlH4 in THF
gave good results (shown via TLC and LC–MS analysis), the
isolated products were not stable and degraded quickly, making
full characterization impossible. Therefore, the crude amino-
methyl compounds 17a–g were directly converted to the corre-
sponding amides 9a–i using different anhydrides or acid chlo-
rides 11a–c. The resulting amides were stable and gained
mediocre to good yields except for amides 9a and 9d (Table 2).
The yield of 9d was found to be very low due to a reductive
replacement of the fluoro atoms of the benzyl ring during the
reduction of the nitrile with LiAlH4. Only a small amount (5%
yield) of the desired compound was isolated. Also, a reductive
replacement was observed during the conversion of 12h,
yielding the intermediate 17a with R1 = Bn instead of R1 =
bromobenzyl. Depending on the nature of the side chain R1 in
compounds 12a–g, the reduction to compounds 17a–g leads to a
change of R1 to a different side chain R1' which can be used for
further transformation to R1'' by conversion with electrophiles.
This was shown with compound 12g (R1 = -CH2CO2Et), being
reduced to compound 17g (R1' = -(CH2)2OH) and acylated to 9i
with R1'' = -(CH2)2OCOMe.
The last step in the synthesis of the target compounds 5a–i
included the cleavage of the triazene unit of the amides 9 with
subsequent cyclization to the final pyrazolo[3,4-d][1,2,3]tri-
azine compounds 5 (Scheme 4). The successful cyclizations
gave the desired pyrazolo[3,4-d][1,2,3]triazines 5 in moderate
to good yields. Not all cyclization products were air-stable.
While compounds 5a–d with a benzylic side chain in R1'' were
stable, a full characterization was possible, especially pyrazolo-
triazines with an aliphatic substituent on the pyrazole-nitrogen
(5e–i) degraded rapidly in contact with air/moisture.
The conversion of the regioisomeric compounds 10 to 6 failed
under the conditions described in Scheme 4. The triazene
protective group could not be cleaved even under harsh condi-
tions (temperatures up to 100 °C in dichloroethane and use of
H2SO4 as acid), and the starting material was recovered in all of
the reactions.
Selected final compounds 5 and intermediates 9, 12, 13, and 17
obtained in this work were tested for their cytotoxicity. We con-
ducted standardized MTT assays [41] to evaluate if the newly
accessible compounds of type 5 and their precursors could
become interesting target molecules for biological investiga-
tions or if the compounds show high toxicity, which might
prevent their use. We monitored cytotoxicity at six different
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Table 2: Synthesis of amides 9a–i via reduction of nitriles 12a–g to pyrazolo-ortho-methylamines and subsequent conversion with aliphatic anhy-
drides or chlorides 11a–c.
entrya 12 R1 (12) 17 11 9 R1'' (9) R2 yield 9 (%)
1 12a Bn 17a 11a 9a Bn Me 23
2b 12a Bn 17a 11b 9b Bn Ph 41
3 12b 4-methylbenzyl 17b 11c 9c p-tolyl-CH2 iBu 61
4b 12c 3,5-difluorobenzyl 17c 11a 9d 3,5-difluorobenzyl Me 5
5 12d ethyl 17d 11a 9e ethyl Me 59
6 12e cyclopentyl 17e 11a 9f cyclopentyl Me 74
7 12e cyclopentyl 17e 11b 9g cyclopentyl Ph 63
8 12f isobutyl 17f 11a 9h isobutyl Me 52
9 12g EtCO2CH2 17g 11a 9i MeCO2(CH2)2 Me 72
aThe reaction consists of two steps. The intermediate compound 17 was isolated but not purified and used as obtained. Conditions: first step: 12,
LiAlH4 (3.0 equiv), THF, 0 °C to 21 °C, then 50 °C. Second step: 11 (X = OCOR2) (1.5 equiv), THF, 0 °C to 21 °C. bIn a modified protocol, acid
chlorides were used instead of anhydrides to introduce R2. The second step was altered as follows: 11 (X = Cl) (1.5 equiv), THF, NEt3 (3.0 equiv),
0 °C to 21 °C.
Scheme 4: Cleavage of the triazene protective group and cyclization of the resulting diazonium intermediate yielding pyrazolo[3,4-d][1,2,3]-3H-triazine
derivatives 5a–i.
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Figure 3: Graphical overview about selected pyrazolo[1,2,3]triazines 5 and intermediates 9, 12, and 13 and their calculated IC50 values after treat-
ment of HeLa cells with different concentrations of the respective compounds.
concentrations ranging from 0.5 µM to 50 µM (for detailed
results, see Supporting Information File 1). It was found that the
exemplarily chosen compounds of type 5, namely 5a, 5d–f, and
5h, did not reduce the viability of the human epithelial cervix
carcinoma (HeLa) cells at every concentration tested. The deriv-
atives of the target compounds of class 5 were chosen as they
were available in sufficient amounts and showed no decomposi-
tion during storage and dilution in DMSO. Also, most of the
intermediates showed no reduction of cell viability; however,
compounds 9b, 12b,c, 13a,b, and 13f–h showed some cyto-
toxic effects at high concentrations.
Interestingly, no common structural motif promoted an increase
in the in vitro cytotoxicity. However, by comparing the IC50
values of the compound classes 12 and 13, regioisomerism
seems to play a decisive role: while compounds 12a and 12d–h
had no influence on the viability of HeLa cells, their regio-
isomers 13a and 13d–h decreased the viability at high micro-
molar concentrations. A slightly increased cytotoxicity of some
derivatives of compound class 12 compared to 13 was observed
for 12b and 12c. The amides 9 had no influence on the viability
except for derivate 9b, characterized by two aromatic moieties
at both variable positions R1 and R2. In Table S3 (Supporting
Information File 1), the results for compounds 5, 9, 12, and 13
are summarized allowing the direct comparison of the toxicity
of the four compound classes with respect to 5 different
residues R1. The full data of the toxicity studies for all obtained
compounds are given in Supporting Information File 1, Tables
S1–S3. Comparing the 20 derivatives depicted in Figure 3
reveals that compounds of the classes 5, 9, and 12 are in general
less toxic than the respective compounds of class 13, at least
with respect to the derivatives that were obtained in this study.
As the IC50 value of every compound tested lies above the con-
centration range that is interesting for biological applications,
we consider molecules of type 5 as feasible for further biologi-
cal screenings. We will continue our studies to search for poten-
tial targets for the versatile pyrazolo[1,2,3]triazine library
presented herein.
Conclusion
In analogy to literature-known acid-induced conversions of
triazene-benzyl acetamides to 3,4-dihydrobenzo[d][1,2,3]tri-
azines, so far not described pyrazolo[3,4-d][1,2,3]-3H-triazines
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5 were successfully synthesized. Altogether nine derivatives
5a–i were synthesized in five steps starting from the commer-
cially available 3-(3,3-diisopropyltriaz-1-en-1-yl)-1H-pyrazole-
4-carbonitrile. The herein given examples were generated by
introducing two side-chains, one on the pyrazole core and the
other as a side chain added to a methylamine intermediate in
step 2 and step 4 of the reaction sequence. Depending on the
introduced side chain, further modifications were obtained
(shown for compound 9g). The triazene protective group toler-
ates the reaction conditions used for the described processes and
is probably compatible with many others described in the litera-
ture. However, limitations are given to acidic reaction media,
which tend to cleave the protective group. So far, the attempts
to synthesize compounds of general structure 6, a regioisomer
of the successfully gained pyrazolo[3,4-d][1,2,3]-3H-triazines
5, failed under similar procedures.
Abbreviations
TFA, trifluoroacetic acid; DMSO, dimethyl sulfoxide; THF,
tetrahydrofuran, TLC, thin-layer chromatography, LC–MS,
liquid chromatography/mass spectrometry.
Supporting Information
The Supporting Information contains detailed descriptions
of the reactions and protocols as well as the
characterization of all target compounds.
Supporting Information File 1
Experimental section and characterization data, biological
assay details, and data availability in chemotion repository.
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supplementary/1860-5397-17-187-S1.pdf]
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